September 09, 2020
Chinese Biotech Sector is Blowing Hot as M&A and IPO Deals Surge Amid Covid-19 Pandemic
Toto Ku, Datasite Senior Sales Director, provides comments on the outlook for the Chinese biotech sector, including the surge in M&A and IPO deals amid the COVID-19 pandemic. The South Morning China Post article highlights findings from a recent webinar discussion on Deal Drivers in the Healthcare and Life Sciences: Mainland China.
-
Datasite for Healthcare
Navigating the healthcare and life sciences industry has never been harder. Whether you’re looking at a licensing, listing or M&A, achieve your objective quickly and keep sensitive data secure with Datasite.
Contacts
Media Relations
Marta Carraro
Vice President, Communications
You may also like:
US M&A Will Continue to Boom After Robust Q1 Deal-Making – Mergermarket US M&A Webinar
By Sydney Halleman in Charlottesville, Virginia, and Yiqin Shen in New York with analytics by Philip Segal High multiples and increased M&A activity are expected to continue in the US after a strong performance in 1Q21, industry experts said during Mergermarket’s M&A Momentum: USA Webinar last week.
Where is ANZ’s Technological Sophistication When it Comes to M&A Processes?
Yoichiro Shimizu, Head of Datasite Japan, discusses key factors holding back the digitization of M&A processes in Australia and New Zealand (ANZ). The article references findings from a recent Datasite report, including the main barriers for dealmakers adopting digital M&A processes, and the technologies that will help accelerate M&A in the next five years.
How digitally mature are M&A processes in ANZ?
Yoichiro Shimizu, Head of Datasite Japan, discusses key factors holding back the digitization of M&A processes in Australia and New Zealand (ANZ). The article references findings from a recent Datasite report, including the main barriers for dealmakers adopting digital M&A processes, and the technologies that will help accelerate M&A in the next five years.
